But postmenopausal women have 29 percent improvement in overall survival
Friday, December 10, 2010 (Last Updated: 12/13/2010)
FRIDAY, Dec. 10 (HealthDay News) -- Adjuvant use of zoledronic acid does not appear to improve disease-free survival among women with stage II/III breast cancer, according a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 8 to 12.
In the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer (AZURE) trial, Robert Coleman, M.D., of the University of Sheffield in the United Kingdom, and colleagues randomized 3,360 patients with stage II/III breast cancer from 174 centers to standard therapy or standard therapy plus zoledronic acid.
The investigators found no difference in disease-free survival in the overall population. However, there was a 29 percent improvement in overall survival among 1,101 patients who were five years post-menopause. The investigators also identified 17 confirmed cases of osteonecrosis of the jaw (1.1 percent).
"To see a survival advantage like this is quite remarkable, and the difference in outcome between this group and the younger population is unlikely to be a chance finding. We will clearly want to investigate further in this population," Coleman said in a statement.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.
October 03, 2014
November 25, 2015